Skip to main content
Publications
Razavi P, Ahmed M, Roush A, Parikh R, Hitchens A, Shen S, Safonov A, Jhaveri K, Robson M, Peacock N, Ma Y, Santarsiero E, Ganapathy V, Shah R, Amaefule A, Lteif A, Blakely J. Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. J Clin Oncol. 2024 May;42(Suppl 16):e12533.
Ghaswalla P, Hitchens A, Candrilli SD, Carrico J, Hicks KA, Wilson E, Mehta D, Panozzo CA. Prevalence of underlying conditions associated with higher risk for severe RSV, influenza, or COVID-19 in adults in the United States, 2017-2018. Poster presented at the IDWeek 2023; October 12, 2023. Boston, MA.
Fasching PA, Hall PS, Chang L, Parikh R, Hitchens A, Davis KL, Sjekloca N, Summerhayes M, Ntalla I, Derrien Ansquer V, Bergamaco E, Ghabaireh M. Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER). Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 11, 2023. Berlin, Germany.
Oikonomidou O, Galve-Calvo E, Wockel A, Parikh R, Hitchens A, Chen C, Gauthier E, Li B, Derrien Ansquer V, Frugier G, Jimenez M, Davis KL, Broughton EI. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2_ advanced breast cancer in Europe. Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 2023. Berlin, Germany.